Orin
PMNYSE·Tobacco

Philip Morris International Inc.

Market cap $317.8BP/E 29.6× trailingGross margin 67.7%Reports Fri 5 Feb 2027, before the open
$202.62
+0.75 (+0.37%)Tue 27 Oct close 16:00 ET
52-wk $142.11 – $210.45
Orin's take
7out of 10 — how sure Orin is of this read

Orin's own judgment of how firmly the evidence points one way — not the chance the price goes up.

Refreshed 21 Oct, the 9th take on PM — written before the latest quarterly or annual filing. An update has been queued since 23 Oct and hasn't run yet.

Philip Morris International's smoke-free transformation is clearly working — FY2025 revenue grew 7.3% to $40.6B with operating margin expanding to 36.6% and diluted EPS surging 60.6% to $7.26, while Q2 2026 revenue accelerated to 10.4% YoY growth at $11.2B and the company just posted its eighth consecutive EPS beat with Q3 2026 actual EPS of $2.36 versus $2.30 estimated.

However, at 28.7x trailing earnings — an 82.4% premium to the peer median of 15.7x — against $48.8B in total debt and negative book equity of -$10.0B, the stock at $199.90 already discounts near-flawless execution, and net insider dispositions of 158,150 shares ($28.8M) over 24 months plus a declining smart money score from 0.21 to 0.084 offer no confirmation that the rally has further to run.

What could go wrong

  • Valuation compression. At 28.7x PE versus peer median 15.7x (82.4% premium) and EV/EBITDA of 19.0x versus 12.4x (52.4% premium), any growth deceleration could trigger a sharp de-rating.
  • Leverage and negative equity. Total debt of $48.8B against negative stockholders' equity of -$10.0B limits financial flexibility; a recent article flagged a $43B debt load alongside the 8.8% dividend increase.
  • ZYN competitive pressure. A Seeking Alpha Q3 preview noted ZYN's competitive position in the U.S. is under pressure, with Q3 and Q4 results critical for justifying PM's premium valuation.
  • Insider and smart money divergence. Net insider dispositions of 158,150 shares ($28.8M) over 24 months and smart money score declining from 0.21 (Q3 2025) to 0.084 (Q2 2026) suggest sophisticated holders are trimming.

What would change my mind

Smoke-free revenue acceleration. Q3 2026 results on October 21 show smoke-free product revenue growth exceeding prior-quarter rates with margin expansionbullish
Deleveraging commitment. Management announces a concrete debt reduction plan or caps dividend growth to prioritize paying down the $48.8B debt loadbullish
ZYN share loss. Q3 or Q4 2026 results show ZYN losing meaningful U.S. market share to competitors, signaling the premium valuation narrative is breakingbearish
Valuation mean reversion. PE premium to peer median narrows below 50% or revenue growth decelerates below 5% YoY for two consecutive quartersbearish

Where this comes from: FY25 fundamentals · Q2 2026 results · earnings vs estimates · peer comparison. Orin's read on PM; not advice.

How has the share price moved?

27 Oct 2025 – 27 Oct 2026

Up 32.2% over twelve months, from $153.21 on 27 Oct 2025 to $202.62 at the Tue 27 Oct 2026 close. Its highest close in that time was $205.58 on 14 Oct 2026; the last close is 1.4% below it.

Jan 2026AprJulOct
    • Green line: the closing price each trading day.
    • Grey line: the average closing price over the last 50 trading days.
    • Dashed amber line: the same over the last 200 trading days — a slower, smoother line.
    • Bars along the bottom: shares traded each day — green when it closed higher than the day before, rose when lower (the most, 18.1M, on 19 Dec 2025).
    • Flags: the company's filings, on the day they were made (a 10-Q is the quarterly report and a 10-K the annual report; an 8-K reports a major event).
    • Rose flags: large share sales by the company's own officers and directors, from the Form 4 each one files after trading.

    Largest holders · 13F Q2 2026

    Money flow
    FilerPositionOf fund
    Capital World Investors$24.1B2.8%
    BlackRock$19.5B0.3%
    Vanguard Capital Management$18.4B0.4%
    Capital Research Global Investors$15.2B2.1%
    State Street$10.1B0.3%
    JPMorgan Chase$8.8B0.5%
    FMR$8.4B0.4%
    Geode Capital Management$7.1B0.4%
    Vanguard Portfolio Management$5.5B0.2%
    Morgan Stanley$4.6B0.2%

    149 of the 815 filers we track · quarter ended Q2 2026 · positions, not flows

    Insiders, last 24 months: 49 Form 4 filings; open-market trades net −$28.8M. Of the 49 on hand, 0 were open-market purchases and 7 sales — the rest are grants, option exercises and tax withholding.

    Ask Orin about PM

    its filings · its transcripts · its numbers

    Orin answers questions about PM from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

    Start 3 free days →

    How is it priced, against its own past and its sector?

    Tue 27 Oct close

    Priced at 29.6× its last 12 months of profit (Tue 27 Oct close) — higher than in all 5 of its last 5 fiscal years (middle 18.7×); the typical Consumer Defensive company on the NYSE is at 21.9×.

    MeasureNowIts usualSector
    P/E29.6×above usual18.7×21.9×
    P/S7.32×above usual4.94×—
    EV/EBITDA19.0×above usual14.5×—
    P/Bbelow zero——
    • P/B: below zero — it owes more than it owns on its books.
    • "Its usual" is the middle of its own last 5 fiscal years.

    P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.

    P/S: the company's total market value divided by one year of revenue. Used when there is no profit to measure.

    EV/EBITDA: the price of the whole company (its shares plus its debt, minus its cash) divided by one year of operating profit before interest, tax and write-downs.

    P/B: the share price divided by the book value per share — what the company owns minus what it owes, as its accounts record it. When book value is tiny, P/B swings wildly and says little.

    What do the analysts who cover it publish?

    10 firms rated it in the last 18 months · 27 Oct

    The analysts' average 12-month price target is $215 (from $201 to $225) — 6% above the Tue 27 Oct close price. That is their published opinion, not Orin's.

    Average price target

    $215

    $201 – $225 · +6% against the last close

    Their ratings
    • 8 buy or overweight
    • 2 hold
    • 0 underweight or sell

    Price target: the share price an analyst publishes for about 12 months ahead. It is the opinion of the firm that wrote it; the average is across the firms that cover the company.

    Overweight / underweight: analysts' rating words: overweight means the firm expects the stock to do better than the others it covers, underweight worse. Their words, not Orin's.

    How is it priced next to the companies it is compared to?

    1 of 1 with a profit

    Priced at 29.6× its last 12 months of profit. Only 1 of the 1 companies it is compared to made a profit (MO 15.5×), so there is no typical P/E.

    CompanyMarket valueP/EEV/EBITDAGross marginNet marginROE
    PMPhilip Morris International Inc.$316B29.6×19.0×67.7%24.8%n/m
    MOAltria Group, Inc.$123B15.5×12.3×69.9%37.8%n/m
    • PM, MO: return on equity is not meaningful (n/m) — book value is below zero.
    • The list of companies is the data vendor's choice, so it can include a company a person would not have picked.

    Market value: the share price times the number of shares — what the whole company is priced at.

    P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.

    EV/EBITDA: the price of the whole company (its shares plus its debt, minus its cash) divided by one year of operating profit before interest, tax and write-downs.

    Gross margin: the share of each $1 of sales left after the direct cost of making what was sold.

    Net margin: the share of each $1 of sales kept as profit after every cost. Below zero, the company lost money.

    ROE: return on equity: one year of profit as a share of the shareholders' money in the business (its book value).

    Is it priced high or low compared with its own past?

    Tue 27 Oct

    Priced at 29.6× its last 12 months of profit (Tue 27 Oct close). It has no full fiscal year on file since its history starts, so there is nothing of its own to compare with.

    • Now29.6×

    P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.

    Fiscal year (FY): the company's own 12-month accounting year, which need not match the calendar year.

    How has its sector been priced?

    Now–Now · Tue 27 Oct

    Consumer Defensive companies on the NYSE were priced at a typical 21.9× their yearly profit (Tue 27 Oct close).

    • Now21.9×
    • Each year is the middle of that calendar year's daily sector P/E; "Now" is the Tue 27 Oct close figure, the same one in the table above.

    Sector P/E: the middle P/E of the companies in the same sector on the same stock exchange, as the data vendor works it out each day.

    What does a cash-flow model say a share is worth?

    computed 27 Oct at $202.92

    A standard cash-flow model puts it at $181 a share — 11% below the $202.92 price it was computed against (27 Oct).

    ModelValue a shareAgainst the price then
    Standard$18111% below $202.92
    Levered$2001% below $202.92

    Discounted cash flow: a model's estimate of what the company is worth today, from the cash it is forecast to make in future years. Small changes in the forecast move it a lot, and it says little about a company that loses money.

    Standard / levered: two versions of the cash-flow model: the standard one counts the cash before the company pays its lenders, the levered one after.